RxDoctor Payments Data

Kristopher Hansen, DO

Medical Oncology · Altoona, PANPI 1326485202

Payments from drug & device makers

$60,746in general payments, 2019–2025

Across 44 payments — averaging $1380.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$60K
  • E.r. Squibb & Sons, L.L.C.$80
  • AstraZeneca$72
  • Bayer$45
  • Pharmacyclics LLC, An Abbvie Company$42
  • Novartis$40
  • plus $311 from 14 others

What the payments were for

  • Food & beverage$606100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$60,746 in reported general payments places this provider in the 50th percentile of 238 medical oncology providers in Pennsylvania.

See all medical oncology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$38,631
Medicare patients
135
Services billed
399

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TibsovoIvosidenib12$395,448
CalquenceAcalabrutinib Maleate24$390,058
Lenalidomide26$386,283
PomalystPomalidomide14$305,969
ZejulaNiraparib Tosylate11$211,191
JakafiRuxolitinib Phosphate11$197,838
XtandiEnzalutamide12$134,775
Imatinib Mesylate14$29,019
CreonLipase/Protease/Amylase17$28,673
Abiraterone Acetate24$25,659
EliquisApixaban39$22,372
Anastrozole79$1,673
Prochlorperazine Maleate129$1,578
Dexamethasone167$1,200
Ondansetron OdtOndansetron97$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$72$390,05824 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$80$305,96914 claims
Astellas Pharma US IncXtandi$11$134,77512 claims
PfizerEliquis$32$22,37239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 238 medical oncology providers in Pennsylvania.

Other medical oncology in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →